In the latest episode of The Ron Lanton Report, published by Pharmaceutical Executive on November 16, 2026, Ron Lanton III spoke with Kevin Caldwell, CEO, President and Co-Founder of Ossium Health, about the company's approach to expanding access to bone marrow transplantation.
Traditional bone marrow transplantation can require months of searching for a suitable living donor. Ossium Health is developing an alternative by recovering, processing and cryopreserving bone marrow from deceased organ donors, creating a bank of cells that can be made available to transplant centers when needed.
The conversation explored the science behind bone marrow preservation, early clinical experience, physician adoption and the operational challenges of expanding access to this technology.
Ossium's approach also raises broader questions for the biotechnology industry. Bringing an advanced therapy to patients requires more than scientific innovation. Manufacturing capacity, regulatory requirements, distribution infrastructure, reimbursement and relationships with healthcare institutions can all influence whether a new technology achieves widespread adoption.
As cell and gene therapies continue to advance, biotechnology companies must address these commercial and operational considerations alongside clinical development.
Watch the full interview on Pharmaceutical Executive.
Lanton, Lanton & Sosa Law advises pharmaceutical, biotechnology and healthcare companies on regulatory matters, commercial agreements, business transactions and commercialization strategies.